Key facts
- It has raised $14.3M; the latest was Later Stage VC ($3.5M) in May 2025.
- Notable investors include Creative Destruction Lab, Investissement Quebec, Keihanna Global Acceleration Program, Government of Canada, Government of Quebec — 15 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 15 names
- ·Watchlist + deal alerts for Zilia
- ·The full record, as it builds
Funding rounds
No funding rounds for Zilia are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Zilia
Developer of a non-invasive medtech platform designed to measure biomarkers in the eye. The company's platform offers advanced imaging, spectrometry, optical analysis and artificial intelligence-based interpretation tools to leverage the eye's optical properties and its connection to the vascular system and brain, enabling eye care professionals and healthcare practitioners to assess physiological changes, identify potential disease indicators, and support earlier intervention.
- Sector
- Healthcare
- HQ
- Quebec, Canada
- Founded
- 2017
- Employees
- 27
- Website
- ziliahealth.com/
- Ownership
- Privately Held (backing)
Zilia doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Zilia shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Zilia in its N-PORT filings yet. We sweep new filings monthly.